Business
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026 Published positive data from its global Phase 2 study supporting potential of rademikibart as a novel biologic treatment for patients with asthma and Type 2 inflammation Strong balance sheet with cash runway into 2027 through key clinical catalysts SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -
About this update from Connect Biopharma Holdings Limited
[{"type":"image","alt":"Connect Biopharma Holdings Limited","displaySize":"","headline":null,"caption":"Connect Biopharma Holdings Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/f3a290cabae4a8e314429e2a9e477131"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d9Dv0E8EdrX1flrzOZWuxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f3a290cabae4a8e314429e2a9e477131","width":300,"height":83}},"lazy":false},{"type":"text","content":"Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026","length":208,"tagName":"p"},{"type":"text","content":"Published positive data from its global Phase 2 study supporting potential of rademikibart as a novel biologic treatment for patients with asthma and Type 2 inflammation","length":169,"tagName":"p"},{"type":"text","content":"Strong balance sheet with cash runway into 2027 through key clinical catalysts","length":78,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today reported financial results for the three months ended March 31, 2025, and provided a business update.","length":396,"tagName":"p"},{"type":"text","content":"“The first quarter of 2025 was very productive, including a positive Type C meeting with the U.S. Food and Drug Administration (FDA), publication of our previously completed global Phase 2 trial results in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), and acceptance of four posters to be presented at the American Thoracic Society (ATS) 2025 International Conference,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “We are focused on execution as we advance our clinical development plan for rademikibart, and we were pleased to initiate the Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations in both asthma and COPD. Based on our recently ...